
Society for Viral Studies

GBM #2 October 17th, 2022



Welcome New Members!



Please sign in using the QR Code for attendance!



What is the Society for Viral Studies?

We aim to encourage scientific discussion, research, and exploration with UF's undergraduate students who are interested in a career in science! We host a variety of meetings, guest lectures, socials, volunteer events, and trips with the common goal of developing the next generation of scientists. There is no major requirement to be involved and we do not charge dues.



Travel | Research | Mentorship | Volunteering | Leadership



Active Member Requirements

01 Be a UF Student **O2** Attend ~ ²⁄₃ of meetings

O3 Attend ~ ½ of events

Benefits

- Priority for trip sign-ups
- Priority for committee positions



Meet Our Faculty Advisor



Dr. Niam Montazeri

Assistant Professor of Food Virology

Department of Food Science and Human Nutrition



Meet the Officers!



Brianna Garcia President



Antonia LoFranco Vice President



Erica Roberts Treasurer



Michele Himadi Secretary



Kira Kazi Event Director



Sophie Penafiel Public Relations Director



Urvi Patel Trip Director

Middle School Outreach

- Ms. Winant of Howard Bishop Middle school is looking for our help in her 6th-8th grade classes!
- Connected us with 6th Grade teacher Ivy Grob
- Cellular Respiration-8th grade: Pushed back to Spring
- January: Pathology-6th grade
- March-May: Ecosystems-7th grade

In November, Ms. Grob will be teaching topics of air pressure and particle motion with her class instead of Cellular Respiration (pushed back to Spring). This opportunity will be an all day commitment and will require transportation to Howard Bishop Middle (carpooling can be coordinated).







Homecoming Festival

Thank you for coming out everyone!







Merch and Other Cool Stuff

- Our NEW T-shirts are for sale! \$20 each
- We still have some of our special stickers!
 - 🌼 🗘 \$3 each
- Rep SVS with logo stickers and buttons! \$1 each
- Grad cords will be available for active members who are graduating.
 - s \$10 each
- For all purchases you can Venmo @ericaroberts or pay in cash :)



How to find research...

Take BCH4905 Science

for Life Seminar!

If your schedule can accommodate it, this class will get your foot in the door and provide a streamlined path to working in a lab.

Our biggest tips:

Attend Research

Fairs/Events

Going to these events let's you speak to research coordinators directly and allows you to explore a variety of research opportunities!

Be persistent!

Of course, be polite, but show your enthusiasm. If you're interested in a specific lab or paper– try contacting all the authors that worked on the paper or ar in the lab you see yourself joining.

Utilize CURBS & Personal connections

Use the CURBS website to look into position postings in areas of research that interest you. Use your connections! Don't be afraid to ask for help from peers, mentors, advisors and teachers!

https://cur.aa.ufl.edu/research-s earch/

Email Examples

My name is Kira Kazi and I am a freshman at the University of Florida enrolled in a course called Science for Life Seminar. As a part of the course, I will be writing a report on a UF faculty member's research after interviewing them and was wonderfing if you would be open to speaking to me about your current research at your lab? I think your research is interesting and integral to opening eyes to the detriments of pollution and would love to learn more.

I hope you are doing well and staying healthy! First and foremost, I want to again say thank you so much for your time in meeting with me to discuss your research and lab for my report. Talking about the type of research you do in your lab and learning more about the technology used to collect data using zebrafish as a model at the university level compared to what I had done in high school was really interesting and one of the highlights of my first semester! You had told me you had room for one more in the lab for the spring, but unfortunately I will not be moving to Gainesville until the fall 2021 semester, so I won't be able to be involved in the spring. I really appreciate the opportunity and your advice on getting involved in research at UF in general as well!

Have a wonderful day, Kira Kazi Dear

I hope this email finds you well. My name is Brianna Garcia, and I am a Microbiology and Cell Science major in CALS. I am contacting you regarding the posting about a research lab position on the CURBS Undergraduate research website for Dr. Lam's Lab. I saw that you work with Dr. Lam as a Graduate Student after reading the research profile on UFCD.

I believe that antimicrobial resistance is a concerning issue that has risen in prevalence over the decades. Being able to understand the virulence of these bacterial pathogens such as *Enterococci* and *Streptococcus* mutans is necessary work.

There is so much for me to learn in this area, and **I** would love the opportunity to volunteer as an undergraduate research assistant in your lab. Please let me know if you have any availability in your lab for the Spring 2022 semester.

Thank you for taking the time to read this. I hope we can work together in the future.

Sincerely,

Brianna Garcia

Our future speakers...



Andrew B Allison,

Assistant Professor – Veterinary Virology

DEPARTMENT: Department of Comparative, Diagnostic & Population Medicine

BUSINESS PHONE: BUSINESS EMAIL: (352) 294-4127 aallison1@ufl.edu

Robert J Ossiboff, DVM, PhD, DACVP Clinical Associate Professor – Aquatic Pathology/Anatomic Pathology

DEPARTMENT:

Department of Comparative, Diagnostic & Population Medicine

BUSINESS EMAIL: rossiboff@ufl.edu cv: View Curriculum Vitae



Journal Article Presentation

- We will now go over a relevant journal article covering ongoing research on diseases, pathology, and how viruses can be utilized as a potential cure.
- The topic?
 - Using the same platform the Covid-19 vaccines were built on to cure/prevent cancer!



But First... Kahoot!



General Research Article Structure

1. Abstract


a. A concise summary for reader to determine usefulness

2. Introduction

- a. Provides context
- b. Outlines the upcoming topics
- 3. Middle (Body)
 - a. Actual dive into information, data analysis, etc.
 - b. Separated into multiple paragraphs and subheadings
- 4. Discussion (Conclusion)
 - a. Discusses the results, data, and information,
 - b. Highlights the limitations of the study/experiment,
 - c. Outlines what future research should focus on



Abstract



Article Analysis (Preview)

mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

Gal Cafri,^{1,2} Jared J. Gartner,¹ Tal Zaks,³ Kristen Hopson,³ Noam Levin,¹ Biman C. Paria,¹ Maria R. Parkhurst,¹ Rami Yossef,¹ Frank J. Lowery,¹ Mohammad S. Jafferji,¹ Todd D. Prickett,¹ Stephanie L. Goff,¹ Christine T. McGowan,¹ Samantha Seitter,¹ Mackenzie L. Shindorf,¹ Anup Parikh,¹ Praveen D. Chatani,¹ Paul F. Robbins,¹ and Steven A. Rosenberg¹

¹Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.²Sheba Medical Center, Ramat Gan, Israel. ³Moderna Inc., Cambridge, Massachusetts, USA.

BACKGROUND. Therapeutic vaccinations against cancer have mainly targeted differentiation antigens, cancer-testis antigens, and overexpressed antigens and have thus far resulted in little clinical benefit. Studies conducted by multiple groups have demonstrated that T cells recognizing neoantigens are present in most cancers and offer a specific and highly immunogenic target for personalized vaccination.

METHODS. We recently developed a process using tumor-infiltrating lymphocytes to identify the specific immunogenic mutations expressed in patients' tumors. Here, validated, defined neoantigens, predicted neoepitopes, and mutations of driver genes were concatenated into a single mRNA construct to vaccinate patients with metastatic gastrointestinal cancer.

RESULTS. The vaccine was safe and elicited mutation-specific T cell responses against predicted neoepitopes not detected before vaccination. Furthermore, we were able to isolate and verify T cell receptors targeting KRAS^{G12D} mutation. We observed no objective clinical responses in the 4 patients treated in this trial.

CONCLUSION. This vaccine was safe, and potential future combination of such vaccines with checkpoint inhibitors or adoptive T cell therapy should be evaluated for possible clinical benefit in patients with common epithelial cancers.

TRIAL REGISTRATION. Phase I/II protocol (NCT03480152) was approved by the IRB committee of the NIH and the FDA.

FUNDING. Center for Clinical Research, NCI, NIH.

Introduction

Introduction

Protective vaccination against infectious diseases has proven to be one of the most effective health measures in medicine; however, therapeutic vaccination against established diseases such as persistent infections and cancer has proven more challenging. Cancer vaccines are designed to target antigens that can elicit selective immune responses against cancer cells and not normal cells. Until recently, therapeutic vaccines against nonviral tumors mainly targeted differentiation antigens, cancer-testis antigens, and/or overexpressed antigens, but with little clinical impact (1).

In recent years, our group and others have extensively studied the importance of neoantigens as targets for immunotherapy (2-7). It is now clear that neoantigen-specific T cells are present in most cancers. Neoantigens derived from somatic

Conflict of interest: TZ is an employee of Moderna and holds equity in the company. KH was an employee of Moderna during the time this study was being conducted. SAR, GC, NL, and RY are inventors on a patent application (no. E-165-2020-0-US-01).

Copyright: © 2020, American Society for Clinical Investigation. Submitted: November 11, 2019; Accepted: July 29, 2020; Published: October 5, 2020. Reference information: J Clin Invest. 2020;130(11):5976–5988. https://doi.org/10.1172/JCI134915. mutations offer a specific and highly immunogenic target for vaccination, and the recent development of rapid and relatively inexpensive technologies for DNA sequencing has facilitated the identification of those targets (2).


Several studies recently reported the vaccination of melanoma patients with neoantigen vaccines (8-10). Although T cell responses could be elicited against a subset of the candidate neoantigens evaluated in these trials, functional validation, including analysis of the ability of T cells to recognize naturally processed and presented antigens, was only carried out for a limited number of reactivities. Although these trials demonstrated the feasibility, safety, and immunogenicity of such vaccines, clear evidence of their clinical efficacy is lacking. An immunogenic vaccination platform capable of encoding multiple tumor-relevant antigens that can be manufactured in a personalized setting is essential for developing neoantigen vaccines for patients with the common epithelial cancers. Furthermore, the selection of vaccine neoantigens that are relevant and immunogenic remains a major hurdle. Here, we developed a pipeline for the selection of defined vaccine neoantigens expressed by the autologous cancer and recognized by the patient's tumor-infiltrating lymphocytes (TILs) that were functionally tested for their immunogenicity. This vaccine, named mRNA-4650, is composed of an mRNA back-

• Why would mRNA be preferred as the sequence of choice over DNA?



- Why would mRNA be preferred as the sequence of choice over DNA?
 - mRNA (+) can be directly translated by cellular machinery (ribosomes)
 - DNA would have to cross nuclear membrane (nucleus) for transcription, then translation
 - Once DNA is in membrane,

can be mutagenic and insert into genome




• Why are these experiments and methods even important? What is so special about immunotherapy?

- Why are these experiments and methods even important? What is so special about immunotherapy?
 - Cancer is constantly evolving
 - Specifically mutated to rapidly replicate
 - Adapts extremely well to current conventional treatments (radiation, chemotherapy)
 - Will over or under express membrane receptors to evade immune cells



Methods and Results



В

Basic concatemer backbone (20 epitopes, 25mer each)



Figure 2. Vaccine design, prior treatments, and safety. (A) Illustration of the pipeline used to select the vaccine antigens. (**B**) The basic concatemer vaccine structure. (**C**) Overview of the vaccination schedule and immune monitoring. W_n , week number. (**D**) Patient-specific timeline of clinical trial progression. (**E**) Summary of preexisting, immunogenic, and nonimmunogenic vaccine antigens. (**F**) Percentage of neoantigen-specific CD8⁺ and CD4⁺ T cells from all patients. (**G**) Number of neoantigen-specific reactivities found in each patient.

Results

Patients and methods. Between March 29, 2018, and November 13, 2019, four patients with metastatic gastrointestinal (GI) cancer were treated with an mRNA



 \wedge

Methods and Results




Fig. 2. Mechanism of action of mRNA vaccines. 1. In a cell-free system, mRNA is in vitro transcribed (IVT) from a DNA template. 2. IVT mRNA is then transfected into dendritic cells (DCs) by the process of (3) endocytosis. 4. Endosomal escape allows entrapped mRNA to be released into the cytoplasm. 5. The mRNA is translated into antigenic proteins using the ribosome translational mechanism. After posttranslational modification, the translated antigenic protein is ready to act in the cell where it was produced. 6. The protein gets secreted by the host cell. 7. Antigen proteins are digested in the cytoplasm by the proteasome and transferred to the endoplasmic reticulum, where they are loaded onto MHC class I molecules (MHC I). 8. MHC I-peptide epitope complexes with loaded MHC Ipeptide epitopes produced, resulting in induction. 9. Exogenous proteins are taken up DCs. 10. They are degraded in endosomes and delivered via the MHC II pathway. Furthermore, to obtain cognate T-cell help in antigen-presenting cells, the protein should be routed through the MHC II pathway. 11. The generated antigenic peptide epitopes are subsequently loaded onto MHC II molecules.

Methods and Results

T. Ye, F. Li, G. Ma et al.

Advanced Drug Delivery Reviews 177 (2021) 113927




Fig. 1. Illustration of the mechanism of action of PCVs in vivo. The main processes are described, including antigen uptake, lysosome escape, antigen presentation, expression of co-stimulation molecules, T cell activation, cytotoxic T cell infiltration and killing tumour cells by induced apoptosis and direct cytolysis. MHC: major histocompatibility complex. TCR: T cell receptor. APC: antigen-presenting cell. CTL: cytotoxic T lymphocyte. PFP: pore-forming protein. GrB: Granzyme B.



How Can Viruses Play A Role?

Inhibitor eg. A20, IRK-M

 \wedge

2

15

Toll-like receptor


CCR7 recept

expensive

Design: Specialized immune cells


response and naive T cell responses

Disadvantage: Cumbersome process and




(a) Whole cell based vaccines

Design: Whole tumor cells used as a vaccine Immunology: Trigger both innate and adaptive immune responses Disadvantage: Poor immunogenecity



(d) DNA-based vaccines

Design: Double-stranded marcomolecule Immunology: Trigger both innate and adaptive immune responses Disadvantage: Low immunogenicity




(b) Viral vector based vaccines

Design: Modified version of a virus Immunology: Can activate innate and adaptive immune responses together Disadvantage: Potential pre-existing immunity, development of host-induced neutralizing antibodies to the vector itself, limiting repeat immunizations



(e) peptide-based vaccines

Design: Based on epitope peptides Immunology: Uses multiple T cell epitopes positioned outside or inside of tumor cells Disadvantage: Difficult to develop due to MHC restrictions and vast heterogeneity in MHC alleles



(c) Dendritic cells-based

vaccines

non-replicating RNA

self-amplicating RNA

Immunology: Capable of boosting a memory T cell

- Act as a delivery vector for mRNA
- Have advantages as well as drawbacks
 - Are great at infecting cells
 - Immune tolerance varies (prior infection)



Results

Conclusions

Nucleotide based prostate cancer immunotherapy with RNActive[®] based compounds such as CV9104 offers a high specificity as only antigen positive tissues are subject to the therapeutic effect. Transient expression of RNActive[®]-based mRNA gives precise control of the pharmacokinetics and dose levels with high safety as RNActive[®]-based mRNA does not exhibit genomic integration. The self-adjuvanted prostate cancer vaccine induces a balanced immune response comprising of a dual activation of the immune system encoding antigens and simultaneously stimulate the innate immune system, effector and memory responses.

The first clinical studies of CV9103 indicate a favorable safety profile of RNActive[®] vaccines and prove their effectiveness. Ongoing clinical trials are set to demonstrate the utility of application in more defined clinical settings. Noteworthy, RNActive[®]-based vaccines can be produced in a highly flexible and versatile process.

- Personalized Cancer Vaccine (PCV) for prostate cancer demonstrated proof of concept
- 80% higher levels of Cytotoxic T-Cells (tumor infiltrating)
- Overall Survivability was extended by 7 months



Viral Outreach

- Thanks to everyone who came to our viral outreach button designing event!
 Everyone made really great designs!
- We will have a button making event soon in the Arts & Crafts Center in the Reitz basement, date TBA
- Counts for volunteer hours
- If you would like to be added to the viral outreach channel, please reach out to Erica on Slack



Upcoming Events



Halloween Party

Thursday, Oct. 27th at 7:30pm Location TBD

GBM 4

Monday, Nov. 14th at 7:30pm Reitz Room 2350 or Zoom https://ufl.zoom.us/j/98737398845




GBM 5

Monday, Nov. 21st at 7:30pm Reitz Room G330 or Zoom https://ufl.zoom.us/j/98737398845

Blaze Pizza Fundraiser

Monday, Nov. 21st 7-10pm Blaze Pizza on SW Archer Road or Mobile Order Bring your friends!



General Information

For more information about active member requirements, ordering viral merchandise, or a calendar of events, please refer to our website or see an officer!

virologyuf.weebly.com



Balance your PIES (physical, intellectual, emotional, sleep) Remove "um" from your vocabulary Question everything When everyone says you can't, keep going Don't limit yourself; keep your options open Don't be scared to ask for help

-Dr. Jim Maruniak , SVS Founder

Join Slack via this QR code!

Final Announcements



Questions?

Thanks for coming!

virology.uf@gmail.com uf-svs.slack.com virologyuf.weebly.com

()

CREDITS: This presentation template was created by Slidesgo, including icons by Flaticon, and infographics & images by Freepik

